<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9650">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05693558</url>
  </required_header>
  <id_info>
    <org_study_id>NVD003-CLN02 CPT</org_study_id>
    <secondary_id>2022-001282-12</secondary_id>
    <nct_id>NCT05693558</nct_id>
  </id_info>
  <brief_title>NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia</brief_title>
  <official_title>A Proof-of-concept Study With NVD-003, an Autologous Osteogenic Bone Graft, in the Treatment of Congenital Pseudarthrosis of the Tibia in Pediatric Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novadip Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novadip Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm, multi-country, multi-center study in pediatric patients, suffering from&#xD;
      congenital pseudarthrosis of the tibia (CPT), treated during the primary surgical&#xD;
      intervention with NVD-003, an autologous 3D scaffold free osteogenic graft.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congenital pseudarthrosis is a rare disorder of unknown aetiology and variable history that&#xD;
      manifests itself as a non-union or pseudarthrosis of fractures that develop spontaneously or&#xD;
      following minor trauma. It can be defined as a disorder of the diaphysis which is revealed by&#xD;
      either pseudarthrosis at birth or by a pathological fracture presenting in bone with&#xD;
      modifications such as bowing, narrowing of the medullary canal or a cyst. Although uncommon,&#xD;
      CPT is the most frequently observed type of congenital pseudarthrosis. Its incidence is&#xD;
      reported to be between 1:140,000 to 1:250,000 live births.&#xD;
&#xD;
      Autologous bone grafting is considered the gold standard approach as this material&#xD;
      vascularizes and integrates with surrounding bone, minimizing the risk of infection,&#xD;
      dislodgement, or break-down.&#xD;
&#xD;
      NVD-003 is a scaffold free 3D osteogenic graft derived from autologous adipose stem cells&#xD;
      which become embedded in their extracellular matrix and combined with&#xD;
      hydroxyapatite/beta-tricalcium phosphate (HA/βTCP) particles.&#xD;
&#xD;
      NVD-003 is intended to promote bone formation, supporting the physiological bone healing&#xD;
      process in severe pathophysiological conditions such as hypoxia, lack of mineralized callus&#xD;
      formation, bone resorption and low osteogenicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single arm, multi-country, multi-center study in pediatric patients, suffering from congenital pseudarthrosis of the tibia (CPT), treated during the primary surgical intervention with NVD-003, an autologous 3D scaffold free osteogenic graft.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective: safety short (≤3 months) and mid long-term (&gt;3-12 months): : Descriptive analysis</measure>
    <time_frame>Up to 12 months post-grafting surgery</time_frame>
    <description>Assess number of patients with NVD-003 related (S)AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term Safety long-term (&gt;12-24 months): Descriptive analysis</measure>
    <time_frame>12-24 months post grafting surgery</time_frame>
    <description>Assess number of patients with NVD-003 related SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tibial length evaluation</measure>
    <time_frame>3-, 6-, 12- and 24-months post-GS</time_frame>
    <description>Assess evolution tibial length (using CT-Scan)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation</measure>
    <time_frame>3-, 6-, 12- and 24-months post-GS</time_frame>
    <description>Assess changes in bone formation (Using Lane and Sandhu Scoring on CT-Scan)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone remodeling</measure>
    <time_frame>3-, 6-, 12- and 24-months post-GS</time_frame>
    <description>Assess changes in bone remodeling (using Lane and Sandhu Scoring on CT-scan)&#xD;
Based on Dual Energy CT-scan (DECT or Spectral CT), information of low- and high-energy photons is collected, allowing to uncover differences in energy-dependent attenuation, facilitating composition of NVD 003 and surrounding tissue and define bone mineral density) at 3-, 6-, and 12-months post-GS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone union</measure>
    <time_frame>3-, 6-, 12- and 24-months post-GS</time_frame>
    <description>Assess changes in bone union (using Lane and Sandhu Scoring on CT-scan)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Congenital Pseudarthrosis of Tibia</condition>
  <arm_group>
    <arm_group_label>NVD-003 bone graft implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study includes 2 important surgical procedures, the Adipose Tissue Collection (ATC) and the Grafting Surgery (GS) and 3 stages&#xD;
Stage 1: A screening, adipose tissue collection &amp; NVD 003 manufacturing period.&#xD;
Stage 2: Grafting surgery and 12-month post-GS follow-up period.&#xD;
Stage 3: long-term safety follow-up period (from post-month 12 to month 24).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NVD-003, an autologous 3D scaffold free osteogenic graft</intervention_name>
    <description>Bone correction and grafting surgery</description>
    <arm_group_label>NVD-003 bone graft implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with congenital pseudarthrosis of the tibia (with or without NF1) and&#xD;
             presenting with a non-healing Paley type 3 or 4 fracture.&#xD;
&#xD;
          -  Minimum weight of 5kg/11lbs.&#xD;
&#xD;
          -  Maximum 2 previous failed surgical orthopaedic interventions to treat the primary CPT&#xD;
             fracture.&#xD;
&#xD;
          -  Acceptable serology and molecular test results excluding the presence of viruses&#xD;
&#xD;
          -  Satisfactory general health condition to undergo surgeries (ATC and GS) with&#xD;
             anaesthesia as per local standards.&#xD;
&#xD;
          -  The patient's parent(s) and/or legal guardian(s) provided written informed consent and&#xD;
             accepted the participation of the patient in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral CPT.&#xD;
&#xD;
          -  Presence of CPT without a fracture of the tibia (Paley type 1 and 2).&#xD;
&#xD;
          -  More than 2 failed surgical attempt(s) to treat the primary tibial fracture.&#xD;
&#xD;
          -  Evidence of plexiform neurofibroma of any size or nodular fibroma ≥ 1.2in/3cm on the&#xD;
             ipsilateral leg.&#xD;
&#xD;
          -  Clinically significant infection at the target grafting site or systemic infection.&#xD;
&#xD;
          -  Presence of clinically significant hematologic, renal, hepatic, and coagulation&#xD;
             laboratory abnormalities (i.e., CBC, PT/INR, Chem-7, and LFTs, etc.).&#xD;
&#xD;
          -  Presence of any auto-immune disease, with exception of well controlled diabetes type 1&#xD;
             or auto-immune thyroid disorders.&#xD;
&#xD;
          -  Any history of experimental therapy with another investigational drug within 60 days&#xD;
             prior to screening.&#xD;
&#xD;
          -  Presence of active tumour.&#xD;
&#xD;
          -  Documented metabolic bone disease or any disorder, such as but not limited to&#xD;
             osteogenesis imperfecta and osteomalacia, that could interfere with the bone healing&#xD;
             and bone metabolism.&#xD;
&#xD;
          -  Chronic, ongoing, or planned use of medications that might affect bone metabolism or&#xD;
             bone quality such as bisphosphonates, steroids, methotrexate, anticoagulant therapies,&#xD;
             immunosuppressant therapy or immunotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip McClure, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Center for Limb Lengthening Baltimore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Louis Docquier</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL St.Luc Brussels</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis Dufrane, MD</last_name>
    <phone>003210827054</phone>
    <email>clinical@novadip.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Houda Khamis, PhD</last_name>
    <phone>003210827054</phone>
    <email>regulatory@novadip.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Adult/Pediatric Limb Lengthening and Reconstruction - International Center for Limb Lengthening - Rubin Institute for Advanced Orthopedics Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip McClure, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Gesheff</last_name>
      <email>Mgesheff@lifebridgehealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Louis Docquier, MD</last_name>
      <email>pierre-louis.docquier@saintluc.uclouvain.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Paley D. Congenital pseudarthrosis of the tibia: biological and biomechanical considerations to achieve union and prevent refracture. J Child Orthop. 2019 Apr 1;13(2):120-133. doi: 10.1302/1863-2548.13.180147.</citation>
    <PMID>30996736</PMID>
  </reference>
  <reference>
    <citation>Dufrane D. Impact of Age on Human Adipose Stem Cells for Bone Tissue Engineering. Cell Transplant. 2017 Sep;26(9):1496-1504. doi: 10.1177/0963689717721203.</citation>
    <PMID>29113460</PMID>
  </reference>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>October 26, 2022</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2023</study_first_posted>
  <last_update_submitted>February 9, 2023</last_update_submitted>
  <last_update_submitted_qc>February 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tissue Engineered Therapy</keyword>
  <keyword>bone graft</keyword>
  <keyword>autologous</keyword>
  <keyword>pediatric</keyword>
  <keyword>congenital</keyword>
  <keyword>non-union</keyword>
  <keyword>pseudarthrosis</keyword>
  <keyword>Cellular therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudarthrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

